Shortcuts

open access

Vol 2, No 3 (2003): Polish Palliative Medicine
Original articles
Published online: 2003-05-29
Get Citation

The effectiveness of strontium 89 in the treatment of pain caused by bone metastases in patients with prostate cancer

Maciej Bączyk, Piotr Milecki, Ewa Bączyk, Jerzy Sowiński
Advances in Palliative Medicine 2003;2(3):141-146.

open access

Vol 2, No 3 (2003): Polish Palliative Medicine
Original articles
Published online: 2003-05-29

Abstract

Background. The aim of this study was to evaluate the effectiveness of strontium 89 (Metastron) therapy in the group of prostate cancer patients with multiple bone metastases.
Material and methods. The study included 70 patients (aged 53–84) with prostate cancer and multiple bone metastases detected by scintigraphy and by radiogram - type of metastases (osteoblastic - 55 patients, osteolytic-osteoblastic - 15 patients). Before strontium therapy 34 out of 70 patients received radiotherapy to the spine to prevent spinal cord compression. For assessment of therapy effectiveness; pain relief (VAS scale), a reduction in analgesic use and motor activity (ECOG and Karnofsky scale) were evaluated.
Results. We have observed statistically significant pain relief and that the analgesic use decreased to 50% of dose on average. The motor activity of the points evaluated according to ECOG scale and Karnofsky scale was much better (p < 0.05).
Conclusions. We conclude that palliative therapy using strontium 89 is effective (88% "good" and "moderate" response rate) and safe for bone pain palliation in patients with multiple prostate cancer bone metastases; it may also improve quality of life.

Abstract

Background. The aim of this study was to evaluate the effectiveness of strontium 89 (Metastron) therapy in the group of prostate cancer patients with multiple bone metastases.
Material and methods. The study included 70 patients (aged 53–84) with prostate cancer and multiple bone metastases detected by scintigraphy and by radiogram - type of metastases (osteoblastic - 55 patients, osteolytic-osteoblastic - 15 patients). Before strontium therapy 34 out of 70 patients received radiotherapy to the spine to prevent spinal cord compression. For assessment of therapy effectiveness; pain relief (VAS scale), a reduction in analgesic use and motor activity (ECOG and Karnofsky scale) were evaluated.
Results. We have observed statistically significant pain relief and that the analgesic use decreased to 50% of dose on average. The motor activity of the points evaluated according to ECOG scale and Karnofsky scale was much better (p < 0.05).
Conclusions. We conclude that palliative therapy using strontium 89 is effective (88% "good" and "moderate" response rate) and safe for bone pain palliation in patients with multiple prostate cancer bone metastases; it may also improve quality of life.
Get Citation

Keywords

bone metastases; pain; strontium 89; radioisotope therapy

About this article
Title

The effectiveness of strontium 89 in the treatment of pain caused by bone metastases in patients with prostate cancer

Journal

Advances in Palliative Medicine

Issue

Vol 2, No 3 (2003): Polish Palliative Medicine

Pages

141-146

Published online

2003-05-29

Page views

533

Article views/downloads

1523

Bibliographic record

Advances in Palliative Medicine 2003;2(3):141-146.

Keywords

bone metastases
pain
strontium 89
radioisotope therapy

Authors

Maciej Bączyk
Piotr Milecki
Ewa Bączyk
Jerzy Sowiński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl